NEW YORK – Chinese precision oncology company Genetron Health said Wednesday that it is collaborating with Darui Biotechnology to support Darui's development of pathogenic microorganism detection products on its sequencer.
The detection kits will run on the Genetron S5 next-generation sequencer. Genetron will also help Darui apply for registration of its reagent kits with regulatory authorities, the company said.
Genetron's next-generation sequencer received approval from China's National Medical Products Association for clinical application and offers low, medium, and high throughput. It has been used to detect tumors, genetic diseases, and pathogenic microorganisms and is based on the Thermo Fisher Scientific Ion GeneStudio S5 system. The Beijing-based firm also received the CE mark for its Detection Kit for Novel Coronavirus RNA in April.
The companies previously collaborated at Wuhan Huoshenshan Hospital during the COVID-19 outbreak, running Darui's detection kits on the Genetron S5 to rapidly test samples. The joint operation "provided comprehensive testing information for clinical study purposes," Genetron said.
"In the outbreak of the COVID-19 pandemic, we are interested in taking preemptive moves to develop research and testing capabilities in response to major public health emergency events,” Genetron CEO Wang Sizhen said in a statement.